217 related articles for article (PubMed ID: 29329420)
1. Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis.
Park SS; Lee DM; Lim JH; Lee D; Park SJ; Kim HM; Sohn S; Yoon G; Eom YW; Jeong SY; Choi EK; Choi KS
Carcinogenesis; 2018 Mar; 39(3):458-470. PubMed ID: 29329420
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Apoptosis; 2010 Apr; 15(4):412-25. PubMed ID: 19856104
[TBL] [Abstract][Full Text] [Related]
4. Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver.
Patel N; Joseph C; Corcoran GB; Ray SD
Toxicol Appl Pharmacol; 2010 Jun; 245(2):143-52. PubMed ID: 20144634
[TBL] [Abstract][Full Text] [Related]
5. Effects of Dahuang zhechong pill on doxorubicin-resistant SMMC-7721 xenografts in mice.
Wu L; Cao KX; Ni ZH; Li WD; Chen ZP; Cheng HB; Liu X
J Ethnopharmacol; 2018 Aug; 222():71-78. PubMed ID: 29609009
[TBL] [Abstract][Full Text] [Related]
6. VCPA, a novel synthetic derivative of α-tocopheryl succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction.
Wu H; Liu S; Gong J; Liu J; Zhang Q; Leng X; Zhang N; Li Y
Cancer Lett; 2017 May; 393():22-32. PubMed ID: 28216375
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL blocks high dose doxorubicin-induced apoptosis but not low dose doxorubicin-induced cell death through mitotic catastrophe.
Park SS; Kim MA; Eom YW; Choi KS
Biochem Biophys Res Commun; 2007 Nov; 363(4):1044-9. PubMed ID: 17923112
[TBL] [Abstract][Full Text] [Related]
8. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
9. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effect of pyrrolidine dithiocarbamate combined with matrine on the growth of human hepatocellular carcinoma xenografts].
Luo N; He S; Tang WX; Zuo GQ; Liao Y
Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):275-80. PubMed ID: 21586226
[TBL] [Abstract][Full Text] [Related]
11. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Miyagi T; Hosui A; Tatsumi T; Ishida H; Noda T; Nagano H; Doki Y; Mori M; Hayashi N
J Hepatol; 2010 May; 52(5):698-704. PubMed ID: 20347499
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.
Chun E; Lee KY
Biochem Biophys Res Commun; 2004 Mar; 315(3):771-9. PubMed ID: 14975768
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma.
Morais C; Healy H; Johnson DW; Gobe G
Nephrol Dial Transplant; 2010 May; 25(5):1462-74. PubMed ID: 20037166
[TBL] [Abstract][Full Text] [Related]
16. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
17. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
18. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
Xu HB; Shen ZL; Fu J; Xu LZ
Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783
[TBL] [Abstract][Full Text] [Related]
19. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin.
Fang S; Qiu J; Wu Z; Bai T; Guo W
Oncotarget; 2017 Jul; 8(30):49783-49795. PubMed ID: 28572537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
